InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
63,199.45
(
-0.01%
)
Post# of 13742
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

budfoxfun

Send PM Follow Ignore
Followers 972
Posts 383062
Boards Moderated 5
Alias Born 06/24/2011

budfoxfun

Re: None

Wednesday, 01/26/2022 10:48:55 AM

Wednesday, January 26, 2022 10:48:55 AM

Post# of 13742
After the recent meeting between Medolife CEO Dr. Mikaelian and DR Vice-President Raquel Peña de Antuña that concluded with interest from the government to register the product as a treatment for COVID-19 in the country, the Company was required to present data to various governmental institutions prior to receiving a governmental order for Escozine, such as:

Program for Essential Medicines and Logistical Support Center (“PROMESE/CAL”)

National Health Insurance (“SeNaSa”)

High-Cost Medicines and Medical Assistance Program (“PMAC”)

QNTA
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up